A Double Blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-00915275 After Oral Administration To Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Pfizer1 site in 1 country40 target enrollmentFebruary 2007

ConditionsDiabetes Mellitus, Type 2

DrugsPF-00915275

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Diabetes Mellitus, Type 2
Sponsor: Pfizer
Enrollment: 40
Locations: 1
Primary Endpoint: The primary end point is glucose lowering (24 hour mean glucose concentration).
Status: Terminated
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-00915275 following administration to adult human subjects with T2DM for 4-weeks. The primary end point is glucose lowering (24 hour mean glucose concentration).

Registry

clinicaltrials.gov

Start Date

February 2007

End Date

June 2007

Last Updated

17 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Pfizer

Eligibility Criteria

Inclusion Criteria

•Type 2 diabetes mellitus
•HbA1c \> 7.5%.

Exclusion Criteria

•Recent (within the past 12 months) evidence or history of unstable concomitant disease.
•Treatment with any oral hypoglycemic agent within 3 months before enrollment.
•The exception to these criteria is that subjects who are currently taking metformin hydrochloride, in a stable dose (that is no changes in dose) for treatment of their diabetes within the past 3 months or longer of enrollment may participate.